Nutraceutical Renews Ephedra Case In Utah Court; FDA To Respond By Jan. 18
This article was originally published in The Tan Sheet
Executive Summary
FDA did not provide advance notice and opportunity for public comment when it "created a new adulteration standard" in its 2004 final rule banning ephedra alkaloids in dietary supplements, Nutraceutical argues in a motion renewing its case against FDA
You may also be interested in...
Experts Debate Precedent Value of Latest Ephedra Decision
Food and drug law experts tell "The Tan Sheet" they take a more reserved view than Nutraceutical Corp. attorney Jonathan Emord of a federal court decision that Emord says ensures FDA's final rule banning ephedra is not a "precedent for the creation of a supplement-wide risk-benefit adulteration standard.
Experts Debate Precedent Value of Latest Ephedra Decision
Food and drug law experts tell "The Tan Sheet" they take a more reserved view than Nutraceutical Corp. attorney Jonathan Emord of a federal court decision that Emord says ensures FDA's final rule banning ephedra is not a "precedent for the creation of a supplement-wide risk-benefit adulteration standard.
Experts Debate Precedent Value of Latest Ephedra Decision
Food and drug law experts tell "The Tan Sheet" they take a more reserved view than Nutraceutical Corp. attorney Jonathan Emord of a federal court decision that Emord says ensures FDA's final rule banning ephedra is not a "precedent for the creation of a supplement-wide risk-benefit adulteration standard.